Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 4
4 · Acrivon Therapeutics, Inc. · Filed Nov 21, 2022
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2022-11-17+888,130→ 888,130 total - Conversion
Series B Preferred Stock
2022-11-17−2,190,131→ 0 total→ Common Stock (888,130 underlying)
Footnotes (1)
- [F1]On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date.